Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Compass Therapeutics Inc’s stock clocked out at $2.10, down -0.47% from its previous closing price of $2.11. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 0.53 million shares were traded. CMPX stock price reached its highest trading level at $2.22 during the session, while it also had its lowest trading level at $2.09.
Ratios:
To gain a deeper understanding of CMPX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.33 and its Current Ratio is at 8.33. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.
On February 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $12.Piper Sandler initiated its Overweight rating on February 19, 2025, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 09 ’25 when GORDON CARL L sold 3,571,428 shares for $1.59 per share. The transaction valued at 5,678,571 led to the insider holds 0 shares of the business.
ORBIMED ADVISORS LLC sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, OrbiMed Genesis Master Fund, L, who serves as the Director of the company, bought 3,571,428 shares for $1.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 290392192 and an Enterprise Value of 184139248. For the stock, the TTM Price-to-Sale (P/S) ratio is 341.64 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 216.634 whereas that against EBITDA is -3.007.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.22, which has changed by 0.34615386 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is 6.52%, while the 200-Day Moving Average is calculated to be 8.37%.
Shares Statistics:
It appears that CMPX traded 1.47M shares on average per day over the past three months and 1021790 shares per day over the past ten days. A total of 138.28M shares are outstanding, with a floating share count of 87.96M. Insiders hold about 36.39% of the company’s shares, while institutions hold 43.19% stake in the company. Shares short for CMPX as of 1745971200 were 7629122 with a Short Ratio of 5.18, compared to 1743379200 on 6618254. Therefore, it implies a Short% of Shares Outstanding of 7629122 and a Short% of Float of 10.459999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Compass Therapeutics Inc (CMPX) is currently drawing attention from 6.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.39 and -$0.56 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.52, with 6.0 analysts recommending between -$0.25 and -$0.67.
